Pacific Edge has clarified the expected timeline for the finalization or withdrawal of the draft Local Coverage Determination (LCD) and the associated Local Coverage Article (LCA) covering the reimbursement of its Cxbladder tests by Medicare, the US national health insurance provider.
The company now understands that Novitas, the Medicare Administrative Contractor with responsibility for its US laboratory, must either finalize or withdraw the proposed LCD and LCA by 9 June 2023 (NZT).
Pacific Edge continues to receive coverage for Cxbladder tests and will update the market as soon as they are aware of additional information related to the LCD and LCA.
See more
